118684-32-5Relevant academic research and scientific papers
Adenosine receptor antagonists
-
, (2020/12/15)
The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.
GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
-
, (2018/01/17)
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
N-alkyl ammonia methylaniline and synthetic, and is used for its polymer anti-corrosion metal surface
-
Paragraph 0026; 0053, (2017/04/11)
The invention discloses N-alkyl aminomethyl aniline as well as synthesis and a polymer thereof and application of the N-alkyl aminomethyl aniline in metal surface anticorrosion. According to the characteristics that after the amine corrosion inhibitor is
QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS
-
, (2014/12/09)
Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
A tetrameric hetero-octanuclear cyclic helicate formed from a bridging ligand with two inequivalent binding sites
Metherell,Ward
, p. 14281 - 14285 (2013/09/02)
A bis-bidentate bridging ligand H2L with inequivalent hard and soft binding sites (catecholate and pyrazolyl-pyridine, respectively) reacts with a mixture of Ti(iv) and Zn(ii) ions to afford an octanuclear heterometallic Ti4Zn4
SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
-
, (2012/04/23)
This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by actinosynnema pretiosum as biocatalyst
Harmrolfs, Kirsten,Bruenjes, Marco,Draeger, Gerald,Floss, Heinz G.,Sasse, Florenz,Taft, Florian,Kirschning, Andreas
, p. 2517 - 2520 (2011/10/08)
Ring closure is possible with seco-proansamitocin and two activated SNAC esters, which can be processed to ansamitocin P3 and 19-deschloro-20-demethoxy AP-3, respectively, by an AHBA-blocked mutant of Actinosynnema pretiosum. This work sheds light on the
Pyrazole glucokinase activators
-
, (2008/06/13)
Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
Substituted cyclic compounds and mixtures comprising same
-
, (2008/06/13)
Novel chemical compounds and mixtures of same are provided having antibacterial and other utilities. The mixtures preferably are formed by reacting a cyclic scaffold moiety with a set of chemical substituients. Libraries formed in accordance with the inve
Dendroid peptide structural mimetics of ω-conotoxin MVIIA based on a 2(1H)-quinolinone core
Guo, Zhao-Xia,Cammidge, Andrew N.,Horwell, David C.
, p. 5169 - 5175 (2007/10/03)
Three mimetics of the peptide ω-Conotoxin MVIIA have been synthesised following the dendroid approach. The three key central amino acids of the natural peptide are mimicked by phenylguanidine (arginine), isopentyl (leucine) and aryl alcohol (tyrosine) att
